Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montine, T. J.
Right arrow Articles by Galasko, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montine, T. J.
Right arrow Articles by Galasko, D.
Related Collections
Right arrowRelated Article
NEUROLOGY 2005;65:768-769
© 2005 American Academy of Neurology
Brief Communications

Lack of ß-methylamino-l-alanine in brain from controls, AD, or Chamorros with PDC

Thomas J. Montine, MD, PhD, Ke Li, BA, Daniel P. Perl, MD and Douglas Galasko, MD

From the Department of Pathology, University of Washington, Seattle.

Address correspondence and reprint requests to Dr Montine, Department of Pathology, University of Washington, Box 359791, Seattle, WA 98104; e-mail: tmontine{at}u.washington.edu

High levels of ß-methylamino-l-alanine (BMAA), a putative neurotoxin, have been reported in brain samples from Chamorros and patients with Alzheimer disease (AD) from western Canada. The authors assayed free BMAA in the brains of five control subjects and five patients with AD from the US Pacific Northwest as well as Chamorros with and without Parkinson–dementia complex. In contrast to others, they detected no free BMAA in any of these samples.

Supported by the Nancy and Buster Alvord Endowment and grants from NIH (AG05136 and AG14382).

Disclosure: The authors report no conflicts of interest.

Received April 19, 2005. Accepted in final form May 6, 2005.


Related Article

September 13 Highlights
Neurology 2005 65: 660-661. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 NeurologyHome page
J. C. Steele and P. L. McGeer
The ALS/PDC syndrome of Guam and the cycad hypothesis
Neurology, May 20, 2008; 70(21): 1984 - 1990.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
W. Yang, R. L. Woltjer, I. Sokal, C. Pan, Y. Wang, M. Brodey, E. R. Peskind, J. B. Leverenz, J. Zhang, D. P. Perl, et al.
Quantitative Proteomics Identifies Surfactant-Resistant {alpha}-Synuclein in Cerebral Cortex of Parkinsonism-Dementia Complex of Guam but Not Alzheimer's Disease or Progressive Supranuclear Palsy
Am. J. Pathol., September 1, 2007; 171(3): 993 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. P. Friedland and C. Armon
Tales of Pacific tangles: Cycad exposure and Guamanian neurodegenerative diseases
Neurology, May 22, 2007; 68(21): 1759 - 1761.
[Full Text] [PDF]

Home page
 NeurologyHome page
A. R. Borenstein, J. A. Mortimer, E. Schofield, Y. Wu, D. P. Salmon, A. Gamst, J. Olichney, L. J. Thal, L. Silbert, J. Kaye, et al.
Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam
Neurology, May 22, 2007; 68(21): 1764 - 1771.
[Abstract] [Full Text] [PDF]

Correspondence:

Read all Correspondence

Lack of ß-methylamino-l-alanine in brain from controls, AD, or Chamorros with PDC
Paul Alan Cox, PhD, et al.
Neurology Online, 22 Dec 2005 [Full text]
Reply from the authors
Thomas J. Montine, et al.
Neurology Online, 22 Dec 2005 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.